121 related articles for article (PubMed ID: 35119047)
1. Cerebellum/liver index in pretherapeutic 18F-FDG PET/CT as a predictive marker of progression-free survival in follicular lymphoma treated by immunochemotherapy and rituximab maintenance.
Godard F; Durot E; Durot C; Hoeffel C; Delmer A; Morland D
Medicine (Baltimore); 2022 Feb; 101(5):e28791. PubMed ID: 35119047
[TBL] [Abstract][Full Text] [Related]
2. 18F-FDG cerebellum/liver index as a prognostic factor for progression-free survival in diffuse large B-cell lymphoma.
Morland D; Zizi G; Godard F; Gauchy AC; Durot C; Hoeffel C; Delmer A; Papathanassiou D; Durot E
Ann Nucl Med; 2021 Jul; 35(7):785-793. PubMed ID: 34031852
[TBL] [Abstract][Full Text] [Related]
3. Pretreatment CT Texture Parameters as Predictive Biomarkers of Progression-Free Survival in Follicular Lymphoma Treated with Immunochemotherapy and Rituximab Maintenance.
Durot C; Durot E; Mulé S; Morland D; Godard F; Quinquenel A; Delmer A; Soyer P; Hoeffel C
Diagnostics (Basel); 2023 Jun; 13(13):. PubMed ID: 37443630
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial.
Trotman J; Barrington SF; Belada D; Meignan M; MacEwan R; Owen C; Ptáčník V; Rosta A; Fingerle-Rowson GR; Zhu J; Nielsen T; Sahin D; Hiddemann W; Marcus RE; Davies A;
Lancet Oncol; 2018 Nov; 19(11):1530-1542. PubMed ID: 30309758
[TBL] [Abstract][Full Text] [Related]
5. Tumor and bone marrow uptakes on [18F]fluorodeoxyglucose positron emission tomography/computed tomography predict prognosis in patients with diffuse large B-cell lymphoma receiving rituximab-containing chemotherapy.
Chang CC; Cho SF; Tu HP; Lin CY; Chuang YW; Chang SM; Hsu WL; Huang YF
Medicine (Baltimore); 2017 Nov; 96(45):e8655. PubMed ID: 29137104
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic role of 18F-fluorodeoxyglucose positron emission tomography for follicular lymphoma with gastrointestinal involvement.
Iwamuro M; Okada H; Takata K; Shinagawa K; Fujiki S; Shiode J; Imagawa A; Araki M; Morito T; Nishimura M; Mizuno M; Inaba T; Suzuki S; Kawai Y; Yoshino T; Kawahara Y; Takaki A; Yamamoto K
World J Gastroenterol; 2012 Nov; 18(44):6427-36; discussion p.6434. PubMed ID: 23197888
[TBL] [Abstract][Full Text] [Related]
7. FDG-PET/CT at the end of immuno-chemotherapy in follicular lymphoma: the prognostic role of the ratio between target lesion and liver SUV
Annunziata S; Cuccaro A; Tisi MC; Hohaus S; Rufini V
Ann Nucl Med; 2018 Jun; 32(5):372-377. PubMed ID: 29464479
[TBL] [Abstract][Full Text] [Related]
8. Follicular Lymphoma Treated with First-Line Immunochemotherapy: A Review of PET/CT in Patients Who Did Not Achieve a Complete Metabolic Response in the GALLIUM Study.
Barrington SF; Mir F; El-Galaly TC; Knapp A; Nielsen TG; Sahin D; Wenger M; Kostakoglu L; Trotman J; Meignan M
J Nucl Med; 2022 Aug; 63(8):1149-1154. PubMed ID: 34857656
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value of total lesion glycolysis of baseline 18F-fluorodeoxyglucose positron emission tomography/computed tomography in diffuse large B-cell lymphoma.
Zhou M; Chen Y; Huang H; Zhou X; Liu J; Huang G
Oncotarget; 2016 Dec; 7(50):83544-83553. PubMed ID: 27835875
[TBL] [Abstract][Full Text] [Related]
10. The prognostic role of post-induction FDG-PET in patients with follicular lymphoma: a subset analysis from the FOLL05 trial of the Fondazione Italiana Linfomi (FIL).
Luminari S; Biasoli I; Versari A; Rattotti S; Bottelli C; Rusconi C; Merli F; Spina M; Ferreri AJ; Zinzani PL; Gallamini A; Franceschetto A; Boccomini C; Franceschetti S; Salvi F; Raimondo FD; Carella AM; Micol Q; Balzarotti M; Musto P; Federico M
Ann Oncol; 2014 Feb; 25(2):442-7. PubMed ID: 24412823
[TBL] [Abstract][Full Text] [Related]
11. Metabolic tumor volume predicts outcome in patients with advanced stage follicular lymphoma from the RELEVANCE trial.
Cottereau AS; Rebaud L; Trotman J; Feugier P; Nastoupil LJ; Bachy E; Flinn IW; Haioun C; Ysebaert L; Bartlett NL; Tilly H; Casasnovas O; Ricci R; Portugues C; Buvat I; Meignan M; Morschhauser F
Ann Oncol; 2024 Jan; 35(1):130-137. PubMed ID: 37898239
[TBL] [Abstract][Full Text] [Related]
12. Outcome of patients with early-stage follicular lymphoma staged with
Ng SP; Khor R; Bressel M; MacManus M; Seymour JF; Hicks RJ; Wirth A
Eur J Nucl Med Mol Imaging; 2019 Jan; 46(1):80-86. PubMed ID: 30083824
[TBL] [Abstract][Full Text] [Related]
13. Positron emission tomography-computed tomography (PET-CT) after induction therapy is highly predictive of patient outcome in follicular lymphoma: analysis of PET-CT in a subset of PRIMA trial participants.
Trotman J; Fournier M; Lamy T; Seymour JF; Sonet A; Janikova A; Shpilberg O; Gyan E; Tilly H; Estell J; Forsyth C; Decaudin D; Fabiani B; Gabarre J; Salles B; Van Den Neste E; Canioni D; Garin E; Fulham M; Vander Borght T; Salles G
J Clin Oncol; 2011 Aug; 29(23):3194-200. PubMed ID: 21747087
[TBL] [Abstract][Full Text] [Related]
14. Prognostic role of pretreatment 18F-FDG PET/CT in primary brain lymphoma.
Albano D; Bertoli M; Battistotti M; Rodella C; Statuto M; Giubbini R; Bertagna F
Ann Nucl Med; 2018 Oct; 32(8):532-541. PubMed ID: 29982990
[TBL] [Abstract][Full Text] [Related]
15. FDG PET/CT predictive role in follicular lymphoma.
Lopci E; Zanoni L; Chiti A; Fonti C; Santi I; Zinzani PL; Fanti S
Eur J Nucl Med Mol Imaging; 2012 May; 39(5):864-71. PubMed ID: 22354449
[TBL] [Abstract][Full Text] [Related]
16. Prognostic Value of Baseline and Interim Total Metabolic Tumor Volume and Total Lesion Glycolysis Measured on 18F-FDG PET-CT in Patients with Follicular Lymphoma.
Liang JH; Zhang YP; Xia J; Ding CY; Wu W; Wang L; Cao L; Zhu HY; Fan L; Li TN; Li JY; Xu W
Cancer Res Treat; 2019 Oct; 51(4):1479-1487. PubMed ID: 30913868
[TBL] [Abstract][Full Text] [Related]
17. Impact of [(18)F]fluorodeoxyglucose positron emission tomography response evaluation in patients with high-tumor burden follicular lymphoma treated with immunochemotherapy: a prospective study from the Groupe d'Etudes des Lymphomes de l'Adulte and GOELAMS.
Dupuis J; Berriolo-Riedinger A; Julian A; Brice P; Tychyj-Pinel C; Tilly H; Mounier N; Gallamini A; Feugier P; Soubeyran P; Colombat P; Laurent G; Berenger N; Casasnovas RO; Vera P; Paone G; Xerri L; Salles G; Haioun C; Meignan M
J Clin Oncol; 2012 Dec; 30(35):4317-22. PubMed ID: 23109699
[TBL] [Abstract][Full Text] [Related]
18. PET/CT assessment in follicular lymphoma using standardized criteria: central review in the PRIMA study.
Tychyj-Pinel C; Ricard F; Fulham M; Fournier M; Meignan M; Lamy T; Vera P; Salles G; Trotman J
Eur J Nucl Med Mol Imaging; 2014 Mar; 41(3):408-15. PubMed ID: 24435770
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of interim and end-of-treatment FDG-PET in follicular lymphoma: a systematic review.
Adams HJA; Nievelstein RAJ; Kwee TC
Ann Hematol; 2016 Jan; 95(1):11-18. PubMed ID: 26576560
[TBL] [Abstract][Full Text] [Related]
20. Basal (18)F-FDG PET/CT in follicular lymphoma: A comparison of metabolic and clinical variables in the prognostic assessment.
Jiménez Londoño GA; García Vicente AM; Poblete García VM; Amo-Salas M; Calle Primo C; Ibañez García Á; Martínez Sanchís B; López-Fidalgo JF; Solano Ramos F; Martínez Hellín A; Díaz Morfa M; Soriano Castrejón Á
Rev Esp Med Nucl Imagen Mol; 2016; 35(5):298-305. PubMed ID: 27312693
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
